SEARCH

SEARCH BY CITATION

References

  • 1
    American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998: 21: 5.
  • 2
    Service FJ, Rizza RA, Zimmerman BR et al. The classification of diabetes by clinical and C-peptide criteria. A prospective population-based study. Diabetes Care 1997: 20: 198201.
  • 3
    Rowley MJ, Mackay IR, Chen Q-Y et al. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 1992: 41: 548551.
  • 4
    Bottazzo GF, Bosi E, Cull CA et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005: 48: 703708.
  • 5
    Davis TM, Wright AD, Mehta ZM et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKDPS 70). Diabetologia 2005: 48: 695702.
  • 6
    Zinman B, Kahn SE, Haffner SM et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004: 53: 31933200.
  • 7
    Brooks-Worrell BM, Greenbaum CJ, Palmer JP et al. Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab 2004: 89: 22222227.
  • 8
    Hathout EH, Thomas W, El-shahawy M et al. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 2001: 107: E102.
  • 9
    Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002: 15: 525530.
  • 10
    Fagot-Campagna A, Pettitt DJ, Engelgau MM et al. Type 2 diabetes among North American children and adolescents: an epidemiological review and public health perspective. J Pediatr 2000: 136: 664672.
  • 11
    Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes in children and adolescents. J Pediatr 2005: 146: 693700.
  • 12
    Reinehr T. Clinical presentation of type 2 diabetes mellitus in children and adolescents. Int J Obes (Lond) 2005: 29 (Suppl. 2): S105S110.
  • 13
    Pinhas-Hamiel O, Standiford D, Hamiel D et al. The type 2 family: a setting for development and treatment of adolescent type 2 diabetes. Arch Pediatr Adolesc Med 1999: 153: 10631067.
  • 14
    Reinehr T, Schober E, Wiegand S, Thon A, Holl R. Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child 2006: 91: 473477.
  • 15
    Scott CR, Smith JM, Cradock MM et al. Characteristics of youth-onset non insulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997: 100: 8491.
  • 16
    Neufeld ND, Rafael LJ, Landon C et al. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care 1998: 21: 8085.
  • 17
    Harris SB, Perkins BA, Whalen-Brough E. Non-insulin-dependent diabetes mellitus among First Nations children. New entity among First Nations people of north western Ontario. Can Fam Physician 1996: 42: 869876.
  • 18
    Glaser NS, Jones KL. Noninsulin-dependent diabetes mellitus in Mexican-American children. West J Med 1998: 168: 11.
  • 19
    Travers SH, Jeffers BW, Bloch CA et al. Gender and tanner stage differences in body composition and insulin sensitivity in early pubertal children. J Clin Endocrinol Metab 1995: 80: 172178.
  • 20
    Silverstein JH, Rosenbloom AL. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2000: 13: 14031409.
  • 21
    Pinhas-Hamiel O, Dolan LM, Zeitler P. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care 1997: 20: 484486.
  • 22
    Arslanian S, Suprasongsin C. Differences in the in vivo insulin secretion and sensitivity of healthy black versus white adolescents. J Pediatr 1996: 129: 440443.
  • 23
    Umpierrez GE, Casals MM, Gebhart SP et al. Diabetic ketoacidosis in obese African Americans. Diabetes 1995: 44: 790795.
  • 24
    American Diabetes Association. Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care 2001: 24: 19881996.
  • 25
    Pettigrew DC. Index of suspicion. Case 2. Diagnosis: hyperglycemic nonketotic hypertonicity (HNKH). Pediatr Rev 2001: 22: 169173.
  • 26
    Morales AE, Rosenbloom AL. Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes. J Pediatr 2004: 144: 270273.
  • 27
    Carchman RM, Dechert-Zeger M, Calikoglu AS, Harris BD. A new challenge in pediatric obesity: pediatric hyperglycemic hyperosmolar syndrome. Pediatr Crit Care Med 2005: 6: 2024.
  • 28
    Bhowmick SK, Levens KL, Rettig KR. Hyperosmolar hyperglycemic crisis: an acute life-threatening event in children and adolescents with type 2 diabetes mellitus. Endocr Pract 2005: 11: 2329.
  • 29
    Pinhas-Hamiel O, Chernausek SD, Zeitler P. Acute necrotizing pancreatitis in an adolescent with type 2 diabetes. Curr Opin Pediatr 2006: 18: 206208.
  • 30
    McDonnell CM, Pedreira CC, Vadamalayan B, Cameron FJ, Werther GA. Diabetic ketoacidosis, hyperosmolarity and hypernatremia: are high-carbohydrate drinks worsening initial presentation? Pediatr Diabetes 2005: 6: 9094.
  • 31
    Fourtner SH, Weinzimer SA, Levitt Katz LE. Hyperglycemic hyperosmolar non-ketotic syndrome in children with type 2 diabetes. Pediatr Diabetes 2005: 6: 129135.
  • 32
    Bradshaw B. The role of the family in managing therapy in minority children with T2DM diabetes mellitus. J Pediatr Endocrinol Metab 2002: 15: 547551.
  • 33
    He J, Goodpaster BH, Kelley DE. Effects of weight loss and physical activity on muscle lipid content and droplet size. Obes Res 2004: 12: 761769.
  • 34
    Gutin B, Cucuzzo N, Islam S et al. Physical training, lifestyle education, and coronary risk factors in obese girls. Med Sci Sports Exerc 1996: 28: 1923.
  • 35
    Hoffman RP, Stumbo PJ, Janz KF et al. Altered insulin resistance is associated with increased dietary weight loss in obese children. Horm Res 1995: 44: 1722.
  • 36
    Willi SM, Martin K, Datko FM et al. Treatment of type 2 diabetes in childhood using a very-low-calorie diet. Diabetes Care 2004: 27: 348353.
  • 37
    Sondike SB, Copperman N, Jacobson MS. Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factor in overweight adolescents. J Pediatr 2003: 142: 253258.
  • 38
    Ebbeling CB, Leidig MM, Sinclair KB et al. A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med 2003: 157: 773779.
  • 39
    Ludwig DS, Majzoub JA, Al-Zahrani A et al. High glycemic index foods, overeating, and obesity. Pediatrics 1999: 103: E26.
  • 40
    Li S, Culver B, Ren J. Benefit and risk of exercise on myocardial function in diabetes. Pharmacol Res 2003: 48: 127132.
  • 41
    Krook A, Holm I, Pettersson S et al. Reduction of risk factors following lifestyle modification program in subjects with type 2 (non-insulin dependent) diabetes mellitus. Clin Physiol Funct Imaging 2003: 23: 2130.
  • 42
    Castaneda C, Layne JE, Munoz-Orians L et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002: 25: 23352341.
  • 43
    Ritenbaugh C, Teufel-Shone NI, Aickin MG et al. A lifestyle intervention improves plasma insulin levels among Native American high school youth. Prev Med 2003: 36: 309319.
  • 44
    Shaibi GQ, Cruz ML, Ball GD et al. Effects of resistance training on insulin sensitivity in overweight Latino adolescent males. Med Sci Sports Exerc 2006: 38: 12081215.
  • 45
    Yamanouchi K, Shinozaki T, Chikada K et al. Daily walking combined with diet is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Diabetes Care 1995: 18: 775778.
  • 46
    Epstein LH, Valoski A, Wing RR et al. Ten-year outcomes of behavioral family-based treatments for childhood obesity. Health Psychol 1994: 13: 373383.
  • 47
    Kawahara R, Amemiya T, Yoshino M et al. Dropout of young non-insulin-dependent diabetics from diabetic care. Diabetes Res Clin Pract 1994: 24: 181185.
  • 48
    Owada M, Nitadori Y, Kitagawa T. Treatment of T2DM diabetes in youth. Clin Pediatr (Phila) 1998: 37: 117121.
  • 49
    Inzucchi SE. Oral antihyperglycemic therapy for T2DM diabetes: scientific review. JAMA 2002: 287: 360372.
  • 50
    Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003: 63: 18791894.
  • 51
    Jones KL, Arslanian S, Peterokova VA et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002: 25: 8994.
  • 52
    Grinstein G, Muzumdar R, Aponte L et al. Presentation and 5-year follow-up of T2DM diabetes mellitus in African-American and Caribbean-Hispanic adolescents. Horm Res 2003: 60: 121126.
  • 53
    Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003: 163: 25942602.
  • 54
    Cryer DR, Nicholas SP, Henry DH et al. Comparative outcomes study of metformin intervention versus conventional approach. Diabetes Care 2005: 28: 539543.
  • 55
    Diamant M, Heine RJ. Thiazolidinedione in type 2 diabetes mellitus. Drugs 2003: 63: 13731405.
  • 56
    Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002: 4: 5659.
  • 57
    Fonseca V. Effect of thiazolidinedione on body weight in patients with diabetes mellitus. Am J Med 2003: 115: 4248.
  • 58
    O’Moore-Sullivan TM, Prins JB. Thiazolidinedione and type 2 diabetes: new drugs for an old disease. Med J Aust 2002: 176: 381386.
  • 59
    Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol 2003: 1: 384387.
  • 60
    Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004: 39: 188196.
  • 61
    Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004: 64: 13391358.
  • 62
    Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001: 358: 17091716.
  • 63
    Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in T2DM diabetes mellitus. Drugs 2001: 61: 16251660.
  • 64
    Ambavane VV, Patil RR, Ainapure SS. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. J Postgrad Med 2002: 48: 246248.
  • 65
    Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of T2DM diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002: 359: 20722077.
  • 66
    Castells S. Management of hyperglycemia in minority children with T2DM diabetes mellitus. J Pediatr Endocrinol Metab 2002: 15: 531540.
  • 67
    Silverstein JH, Rosenbloom AL. Treatment of T2DM diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2000: 13: 14031409.
  • 68
    Zuhri-Yafi MI, Brosnan PG, Hardin DS. Treatment of T2DM diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2002: 15: 541546.
  • 69
    Kavey RE, Daniels SR, Lauer RM et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. J Pediatr 2003: 142: 368372.